Provided by Tiger Trade Technology Pte. Ltd.

NeuroPace Inc.

14.13
-0.3700-2.55%
Volume:7K
Turnover:101.06K
Market Cap:481.74M
PE:-24.83
High:14.47
Open:14.46
Low:14.13
Close:14.50
52wk High:19.60
52wk Low:9.22
Shares:34.09M
Float Shares:23.28M
Volume Ratio:0.25
T/O Rate:0.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5690
EPS(LYR):-0.6560
ROE:-103.27%
ROA:-7.47%
PB:40.54
PE(LYR):-21.54

Loading ...

Nippon Paper Industries to Temporarily Suspend Hungarian EV Battery Material Subsidiary

MT Newswires Live
·
Sep 07

NeuroPace to Present Fireside Chat at Cantor Global Healthcare Conference

Reuters
·
Sep 02

3 Stocks Estimated To Be Undervalued By Up To 37.3% Offering Potential Opportunities

Simply Wall St.
·
Aug 22

NeuroPace Forecasts 2026 Revenue USD 99.5 Million-101.5 Million

Reuters
·
Aug 12

NeuroPace, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

NeuroPace Rugi Bersih GAAP Q2 FY26 Menyempit 38,1% Jadi USD 6,2 Juta; Revenue Naik 17% Jadi USD 22,8 Juta

Reuters
·
Aug 12

NeuroPace, Inc. Q2 EPS Usd -0.18

Reuters
·
Aug 12

Neuropace, Inc. Q2 EPS Usd -0.18

THOMSON REUTERS
·
Aug 12

Press Release: NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

Dow Jones
·
Aug 12

NeuroPace, Inc. Expected to Post a Loss of 21 Cents a Share - Earnings Preview

Reuters
·
Aug 08

Analysts Conflicted on These Healthcare Names: Biogen (BIIB), NeuroPace (NPCE) and Gilead Sciences (GILD)

TIPRANKS
·
Jul 30

NeuroPace: FDA seeks additional clinical evidence from NAUTILUS trial

TIPRANKS
·
Jul 29

NeuroPace Price Target Maintained with a $20.00/Share by HC Wainwright & Co.

Dow Jones
·
Jul 29

NeuroPace faces FDA setback on epilepsy label expansion

TIPRANKS
·
Jul 29

NeuroPace Says FDA Deems Epilepsy Label Expansion Filing not Approvable in Current Form

Reuters
·
Jul 29

Neuropace - Receives FDA Notice Pma Supplement for Ige not Approvable in Current Form

THOMSON REUTERS
·
Jul 29

Neuropace - to Submit Submission Issue Request and Amend Pma Supplement

THOMSON REUTERS
·
Jul 29

Neuropace Receives FDA Guidance on Pma Supplement for Indication Expansion into Idiopathic Generalized Epilepsy

THOMSON REUTERS
·
Jul 29

Neuropace - FDA Requests Additional Clinical Evidence from Nautilus Trial for Pma Supplement

THOMSON REUTERS
·
Jul 29

Neuropace Inc : Mizuho Initiates Coverage with Outperform Rating; Target Price $22

THOMSON REUTERS
·
Jul 23